Stull said that a number of prescription treatments exist for topical psoriasis, such as steroids and injectable therapies, ...

psoriasis drugs market is expected to expand significantly, growing from an estimated USD 19.65 billion in 2024 ...

Study highlights the efficacy and safety of tildrakizumab in improving physical, psychological, and social aspects of quality ...

Emkay Global Financial is bullish on Sun Pharma has recommended buy rating on the stock with a target price of Rs 2400 in its ...

Can a protein involved in delivering Vitamin D to target tissues have an altered serum profile in psoriasis patients with ...

Symptoms include thick areas of discolored skin covered with scales called plaques. Psoriasis is a chronic skin condition that can flare up unexpectedly. Presently, there is no cure for this ...

doi:10.1111/jdv.13891 Imafuku S, Zheng M, Tada Y, et al. Asian consensus on assessment and management of mild to moderate plaque psoriasis with topical therapy. J Dermatol. 2018;45(7):805-811.

Wouldn’t it be great to sail through the rest of winter with soft skin? For the 78 percent of us bothered by itchy or sore ...

Mizuho Securities analyst Uy Ear has maintained their bullish stance on ARQT stock, giving a Buy rating on January 13.Stay Ahead of the ...

UCB SA (OTCMKTS:UCBJY – Get Free Report)’s stock price passed below its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $96.49 and traded as low as $93.22.

UCB, a global biopharmaceutical company, announced today that a single-injection 2 mL prefilled syringe and autoinjector, each containing 320 mg of BIMZELX® (bimekizumab-bkzx) is now available. These ...

UCB announced that a single-injection 2 mL prefilled syringe and autoinjector, each containing 320 mg of BIMZELX is now available.